Horizon Joins UK Cancer Initiative; Will Supply Cell Lines to Study Senescence | GenomeWeb
Horizon Discovery this week announced that it will become the first corporate member of a consortium launched by Cancer Research UK to form teams of academic and pharmaceutical scientists to study emerging areas of cancer research, and translate basic science into new cancer drugs and diagnostics.
 
Alongside Horizon, the consortium, called VIMCAD, comprises Cancer Research UK’s Cambridge Research Institute, St. George’s University of London, the University of Glasgow, and the University of Liverpool.
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.